Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) and French pharma major Sanofi (Euronext: SAN) on Saturday presented ...

Sanofi and Regeneron said that drug candidate didn’t meet primary endpoint in a phase three study, although a benefit was ...

Data from prior Sanofi/Regeneron studies further supports ... on high-dose ICS plus placebo. The VESTIGE trial, meanwhile, demonstrated that dupilumab led to reductions in mucus plugging and ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieve ...